A group of cyclic imides was synthesized by reaction of amino-substituted benzenesulfonamides with a series of acid anhydrides such as succinic, maleic, tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid anhydride, and substituted phthalic anhydrides. The synthesized sulfonamides were evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors against the human (h) isoforms hCA I, II, IV and IX, involved in a variety of diseases among which glaucoma, retinitis pigmentosa, etc. Some of these sulfonamides showed effective inhibitory action (in the nanomolar range) against the cytosolic isoform hCA II and the transmembrane, tumor-associated one hCA IX, making them interesting candidates for preclinical evaluation in glaucoma or various tumors in which the two enzymes are involved. hCA I and IV were on the other hand less inhibited by these sulfonamides, with inhibition constants in the micromolar range.
Introduction
In previous works from these and other groups, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] the preparation and biological activity of cyclic imides incorporating primary sulfonamide moieties were investigated. Phthalimides were definitely the privileged such scaffolds, being shown that they may lead to effective inhibitors of the metallo-enzyme carbonic anhydrase (CA, EC 4.2.1.1). 2, [8] [9] [10] [11] Furthermore, some substituted-phthalimides derived from aromatic sulfonamides such as sulfanilamide, metanilamide or aminoalkyl-benzenesulfonamides, not only showed low nanomolar activity as CA inhibitors (CAIs), but some of them were also highly isoform-selective inhibitors for several CAs involved in relevant pathologies such as glaucoma, 12 epilepsy, 13 obesity, 14 or cancer. 15 Indeed, of the 15 different human(h) CA isoforms known to date, many are involved in such and other pathologies, 16 and finding isoform-selective inhibitors is rather challenging, although many such compounds belonging to various classes of inhibitors were reported by now to possess such properties. 17 Sulfonamides are in clinical use as CAIs for more than 70 years, primarily as antiglaucoma agents or diuretics. [12] [13] [14] [15] [16] [17] Continuing our interest in sulfonamide CAIs, in this work we report the synthesis and human (h) hCA I, II, IV and IX inhibitory activity of cyclic imides obtained from amino-substituted benzenesulfonamides and a series of acid anhydrides such as succinic, maleic, tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid anhydride, and substituted phthalic anhydrides.
Results and discussion

Drug design and chemistry
The lead molecules for designing the CAIs synthesized here were the sulfanilamides incorporating phthalimides moieties reported earlier by one of these groups. In the present work we have included diverse anhydrides for the preparation of the imides, among which succinic, maleic, tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid anhydride, substituted phthalic anhydrides and norbornene dicarboxylic anhydride. In this way, a wider range of chemical space is being explored in order to investigate the effects of the cyclic imide scaffold on the biological activity of these new sulfonamides.
The preparation of designed imides analogues 1-15 is shown in Schemes 1 and 2. Condensation of acid anhydrides with 4-(2-aminoethyl)benzenesulfonamide in refluxing acetic acid afforded imides 1-12 in good yields (Scheme 1). [1] [2] [3] [4] [5] [6] The remaining compounds, 13-15 (Scheme 2) were prepared in a similar manner, but in this case the norbornene dicarboxylic anhydride has been employed, leading to the tricyclic sulfonamides 13-15. Such scaffolds were not employed earlier for obtaining CAIs.
Compounds 1-15 have been characterized in detail by physicochemical methods which confirmed their structures (see Experimental for details).
Carbonic anhydrase inhibition
The newly synthesized compounds 1-15 were screened for their CA inhibitory activity by a stopped-flow CO 2 hydrase assay 18 against the following isoforms: hCA I, II (cytosolic isoforms involved in glaucoma 13 and possibly other pathologic states) 19 and hCA IV (an isoform involved in glaucoma and other eye diseases, such as retinitis pigmentosa), 20 as well as the transmembrane, tumor-associated hCA IX 15,21 see Table 1 .
The following structure-activity relationships (SARs) are observed and reported for these series of compounds:
(i) The slow cytosolic isoform hCA I was inhibited by all the investigated compounds with inhibition constants ranging between 49.2 and 5121 nM. Sulfonamides incorporating tetrahydrophthalimido and tert-butyl phthalimido moieties 3 and 7 showed the best inhibitory activity (K I of 49.2 and 95.7 nM, respectively). The other scaffolds were less potent and inhibited this isoform in the high nanomolar range (K I ranging between 179 and 865 nM). An interesting case was constituted by the isosteric substitution of the chlorine atoms in the phthalimido compounds 9 with bromine, in 10, which led to a significant decrease of the inhibitory potency. Considering the monocyclic imides 1, 2 and the bicyclic scaffold 3-15, the inhibition potency against the hCA I did not vary significantly, except for compound 3, which was the best inhibitor in the subseries. The linker between the hexachloronorbornene dicarboxylic scaffold and the sulfonamide part of the molecules present in 13, 14 and 15 also modulated the inhibition profile. The introduction of a methylene chain, as in 14, increased the inhibition potency from 390 nM (13) to 201 nM (14), but a further chain elongation, as in 15, decreased two times the K I for the last compound. showed a very good inhibition activity against this isoform, with a K I of 5 nM. The replacement of the monocyclic imido scaffold with a bicyclic one did not have a significant effect on the inhibition profiles of these sulfonamides (Table 1) . Only in the case of the pyrazine containing sulfonamide 4, a decreased inhibitory potency was observed compared to the other members of the series, this compound being one of the weakest hCA II inhibitor (K I of 426 nM). The substitution on the phthalimido scaffold in compounds 5-12 did not lead to significant changes in the inhibition potency, except for the tetrabromo-substituted compound 10, which was a medium potency -weak hCA II inhibitor (K I 693 nM). Furthermore, the substitution of the nitro group from position 5 of compound 11 to position 4 (12), increased nearly two times the potency of the corresponding sulfonamide against this. Unlike the other cytosolic isoform, the introduction of a linker in the norborneneimido derivatives 13-15 had diverse effects on the inhibition profile: a decrease of the potency was observed for a methylene linker (13, a K I of 41.5 nM whereas 14 had a K I of 54.6 nM), whereas a further chain elongation, as in 15, led to an increase of the potency with a K I of 23.2 nM for the last compound. (iii) The membrane-bound hCA IV was inhibited by most of compounds investigated here in the micromolar range. The monocyclic imido derivatives 1 and 2 showed K I s in the range of 4.85-9.57 lM. The maleimido scaffold present in 3 led to a compound which was two times more potent than the succinimido analog 1. Also for this isoform, the groups + Acetic acid, Reflux, 6h
Scheme 2. Synthesis of the designed hexachloro norbornene dicarboxylic imides derivatives 13-15. present on the phthalimido scaffold did not influence significantly the inhibition profile. The compounds incorporating hexachloronorbornene dicarboxylic scaffolds, 13-15, showed a very interesting inhibition profile. The linker between the imido scaffold and the sulfonamide head was crucial for the inhibition potency. A direct correlation between the length of the linker and the inhibition constant was observed: 13 showed a nanomolar inhibition constant (K I 83 nM), whereas an increase in the linker length to a methylene or an ethylene group led to a drastic decrease of potency, to the micromolar range (K I of 912 nM for compound 14 and K I of 6764 nM for 15). (iv) hCA IX, the tumor-associated isoform, was effectively inhibited by many of the compounds reported here, in high nanomolar range except for compounds 13 and 14 which were active in the low nanomolar range. The monocyclic imido derivatives 1 and 2 had nearly the same inhibition profile with a K I of 296 nM and 274 nM, respectively. The phthalimido scaffold present in 5-12 led to high nanomolar hCA IX inhibitors, except for nitro-substituted compounds 11 and 12. For these compounds the potency has decreased to the micromolar range, with K I of 1636 nM and 2667 nM, respectively. Moreover, the hexachloro-norbornene scaffold present in 13-15, led to an interesting SAR for the inhibition of this isoform. Compounds 13 and 14 incorporating no linker or a methylene linker, exhibited low nanomolar K I s whereas the derivative with a longer chain 15, as for isoform hCA IV, led to a marked decreased in the inhibition potency (Table 1) .
Conclusions
We investigated a series of cyclic imides as CA inhibitors, continuing our research in this field of enzyme modulators. The compounds were synthesized by reaction of amino-substituted benzenesulfonamides with a series of dicarboxylic acid anhydrides such as succinic, maleic, tetrahydrophthalic, pyrazine-2,3-dicarboxylic acid anhydride, as well as substituted phthalic anhydrides. The synthesized sulfonamides were evaluated for the inhibition of isoforms hCA I, II, IV and IX, involved in a variety of diseases among which glaucoma, retinitis pigmentosa, tumors, etc. They showed effective inhibitory action against the cytosolic isoform hCA II and the transmembrane, tumor-associated one hCA IX, making them interesting candidates for preclinical evaluation in glaucoma or various tumors in which the two enzymes are involved. hCA I and IV were on the other hand less inhibited by these sulfonamides.
Experimental part
Chemistry
Melting points (uncorrected) were recorded on Barnstead 9100 Electrothermal melting apparatus. IR spectra were recorded on a FT-IR Perkin-Elmer spectrometer. A mixture of 4-(2-aminoethyl)benzenesulfonamide (0.5 g, 2.5 mmol), anhydrous sodium acetate (0.41 g, 5.0 mmol) and an acid anhydride (2.5 mmol) was stirred in glacial acetic acid (15 mL). The mixture was heated under reflux for 12 h and the reaction was monitored with the help of TLC. After completion of reaction the solvent was removed under reduced pressure and the crude solid obtained was washed with water, dried and recrystallised from an appropriate solvent.
4.1.1.1. 4-(2-(2,5-Dioxopyrrolidin-1-yl)ethyl)benzenesulfonamide (1) . 3, 3a, 4, 7, 7a -hexahydro-2H-isoindol-2-yl) ethyl)benzenesulfonamide (3) . 33, 33.09, 38.86, 42.74, 127.08, 129.33, 142.30, 142.42, 142.78, 179.94; C 16 (5, pyrazin-6-yl) ethyl)benzenesulfonamide (4) . 22.00, 34.19, 38.62, 123.17, 123.80, 126.30, 129.19, 132.20, 134.76, 142.41, 142.50, 145.43, 167.91, 168.02; C 17 H 16 N 2 O 4 S: m/z (344.07).
4-(2-
. 34.22, 35.73, 38.61, 120.30, 123.13, 126.32, 129.18, 131.22, 132.07, 142.39, 142.46, 158.56, 167.88, 168.26; C 20 4.1. ethyl)benzenesulfonamide (8) . 2H, J = 7.5 Hz), 7.31 (s, 2H), 2H, J = 8.0 Hz), 2H, J = 8.5 Hz), 2H, J = 8.5 Hz); 13 C NMR (125 MHz, DMSO-d 6 ) : d 33.78, 39.34, 125.74, 126.26, 129.67, 131.88, 137.81, 142.80, 166.32; C 16 H 12 Cl 2 N 2 O 4 S: m/z (398.60).
4.1. 2H, J = 7.5 Hz), 7.32 (s, 2H), 2H, J = 8.5 Hz), 2H, J = 6.0 Hz), 1H, J = 5.0 Hz), 1H, J = 5.5 Hz), 1H, J = 5. 72, 39.44, 123.44, 126.29, 127.32, 128.80, 129.65, 133.92, 136.70, 142.82, 142.89, 144.76, 163.65, 166.19; C 16 H 13 N 3 O 6 S: m/z (374.54).
4.1.2. General procedure for the synthesis of cyclic imides 13-15 A mixture of benzenesulfonamide (2.5 mmol), anhydrous sodium acetate (0.41 g, 5.0 mmol) and 4,5,6,7,8,8-hexachloro3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1,3-dione (0.927 g, 2.5 mmol) were stirred in glacial acetic acid (15 mL) and heated under reflux for 6 h. After the evaporation of the solvent under reduced pressure, the precipitate obtained was washed with water, dried and re-crystallised from an appropriate solvent. 4.1.2. [1] [2] [3] [4] 5, 6, 7, 8, 3, 3a, 4, 7, 5, 6, 7, 8, 3, 3a, 4, 7, 49, 52.09, 79.43, 104.37, 126.39, 129.74, 130.58, 138.23, 143.87, 170.05; C 16 H 10 Cl 6 N 2 O 4 S: m/z (539.50). (4, 5, 6, 7, 8, 3, 3a, 4, 7, 60, 52.17, 79.26, 104.36, 126.41, 129.20, 130.71, 141.39, 143.04, 170.38; C 17 H 12 Cl 6 N 2 O 4 S: m/z (552.19).
Carbonic anhydrase inhibition
An SX.18MV-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic/inhibition of various CA isozymes. 18 Phenol Red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.4) as buffer, 0.1 M Na 2 SO 4 or NaClO 4 (for maintaining constant the ionic strength; these anions are not inhibitory in the used concentration), 22 following the CAcatalyzed CO 2 hydration reaction for a period of 5-10 s. Saturated CO 2 solutions in water at 25°C were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 10 mM (in DMSO-water 1:1, v/v) and dilutions up to 0.01 nM done with the assay buffer mentioned above. At least 7 different inhibitor concentrations have been used for measuring the inhibition constant. Inhibitor and enzyme solutions were preincubated together for 10 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. Triplicate experiments were done for each inhibitor concentration, and the values reported throughout the paper are the mean of such results. The inhibition constants were obtained by non-linear least-squares methods using the Cheng-Prusoff equation, as reported earlier, 11 and represent the mean from at least three different determinations. All CA isozymes used here were recombinant proteins obtained as reported earlier by our group.
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